Axitinib as a third or further line of treatment in renal cancer: a single institution experience
Abstract Background Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeut...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2020-06-01
|
| سلاسل: | BMC Urology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://link.springer.com/article/10.1186/s12894-020-00618-1 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|